IMDX
HEALTHCAREInsight Molecular Diagnostics Inc
$5.03+0.45 (+9.83%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IMDX Today?
No stock-specific AI insight has been generated for IMDX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.33$8.51
$5.03
Fundamentals
Market Cap$162M
P/E Ratio—
EPS$-1.65
Dividend Yield—
Dividend / Share—
ROE-236.0%
Profit Margin—
Debt / Equity—
Trading
Volume643K
Avg Volume (10D)—
Shares Outstanding32.3M
IMDX News
20 articles- iMDx to Release First Quarter 2026 Results on May 13, 2026Yahoo Finance·May 6, 2026
- How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx MilestonesYahoo Finance·Apr 29, 2026
- Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure AssayYahoo Finance·Apr 14, 2026
- Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA CatalystYahoo Finance·Apr 13, 2026
- How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA CatalystYahoo Finance·Mar 30, 2026
- Insight Molecular Diagnostics Inc. Q4 2025 Earnings Call SummaryMoby·Mar 27, 2026
- Insight Molecular Diagnostics: Q4 Earnings SnapshotYahoo Finance·Mar 26, 2026
- IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 ResultsYahoo Finance·Mar 26, 2026
- iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare ConferenceYahoo Finance·Mar 20, 2026
- How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Capital And GraftAssureDx MilestonesYahoo Finance·Mar 14, 2026
- Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model ScoreYahoo Finance·Mar 13, 2026
- Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA SubmissionYahoo Finance·Mar 3, 2026
- How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx CatalystYahoo Finance·Feb 27, 2026
- iMDx Announces $26.0 Million Registered Direct OfferingYahoo Finance·Feb 11, 2026
- Insight ‘congratulated’ STAR working group on organ health testing paperYahoo Finance·Jan 14, 2026
- IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant MonitoringYahoo Finance·Jan 13, 2026
- iMDx Announces “JPM Week” and “BTIG Snowbird” Conference ParticipationYahoo Finance·Jan 7, 2026
- iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay LaunchYahoo Finance·Jan 6, 2026
- iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears CompletionYahoo Finance·Jan 5, 2026
- Insiders Rewarded With US$5.2m Addition To Investment As Insight Molecular Diagnostics Stock Hits US$183mYahoo Finance·Dec 28, 2025
All 20 articles loaded
Price Data
Open$5.27
Previous Close$4.58
Day High$5.34
Day Low$4.39
52 Week High$8.51
52 Week Low$2.33
52-Week Range
$2.33$8.51
$5.03
Fundamentals
Market Cap$162M
P/E Ratio—
EPS$-1.65
Dividend Yield—
Dividend / Share—
ROE-236.0%
Profit Margin—
Debt / Equity—
Trading
Volume643K
Avg Volume (10D)—
Shares Outstanding32.3M
About Insight Molecular Diagnostics Inc
OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.
HEALTHCAREDIAGNOSTICS & RESEARCH
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDIAGNOSTICS & RESEARCH
CIK—
Composite FIGI—
Share Class FIGI—